Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00243074 · OUTCOME

Overall Response Rate

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery · Source last updated 2018-01-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Disease assessments for response were performed every 8 weeks for as long as the patient remained on protocol treatment, up to 5 years.

What was measured

confirmed complete and partial responses per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.".

Analysis population: Eligible patients who received any amount of AZD2171

Groups in this outcome

AZD2171 (Cediranib Maleate)

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD2171 (Cediranib Maleate)47

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD2171 (Cediranib Maleate)9Not reported220Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2
        upper Limit
        20
        value
        9
denoms
  1. counts
    1. group Id
      OG000
      value
      47
    units
    Participants
description
confirmed complete and partial responses per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.".
dispersion Type
95% Confidence Interval
groups
  1. id
    OG000
    title
    AZD2171 (Cediranib Maleate)
param Type
NUMBER
population Description
Eligible patients who received any amount of AZD2171
reporting Status
POSTED
time Frame
Disease assessments for response were performed every 8 weeks for as long as the patient remained on protocol treatment, up to 5 years.
title
Overall Response Rate
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice